

1 **Title: A randomized clinical trial of a booster dose with low versus standard dose of**
2 **AZD1222 in adult after 2 doses of inactivated vaccines**

3

4 Sira Nanthapaisal, MD, PhD^{a,l,m}, Thanyawee Puthanakit, MD^b, Peera Jaru-Ampornpan, PhD^c,
5 Rapisa Nantaneee, MD^{b,d}, Pimpayao Sodsai, PhD^e, Orawan Himananto^f, Jiratchaya
6 Sophonphan, MSc^g, Pintip Suchartlikitwong, MD^h, Narin Hiransuthikul, MD, PhDⁱ,
7 Pornpimon Angkasekwinai PhD^{j,k,l}, Auchara Tangsathapornpong MD^{a,l}* Nattiya Hirankarn,
8 MD, PhD^{e*} on behalf of the study team**

9

10 ^aDepartment of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani,
11 Thailand

12 ^bCenter of Excellence in Pediatric Infectious Diseases and Vaccines, Department of
13 Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

14 ^cVirology and Cell Technology Research Team, National Center for Genetic Engineering and
15 Biotechnology (BIOTEC)

16 ^dPediatric Allergy and Clinical Immunology Research Unit, Division of Allergy and
17 Immunology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University,
18 Bangkok, Thailand

19 ^eCenter of Excellence in Immunology and Immune-mediated Diseases, Department of
20 Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

21 ^fMonoclonal Antibody Production and Application Research Team, National Center for
22 Genetic Engineering and Biotechnology (BIOTEC)

23 ^gThe HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red
24 Cross AIDS Research Centre, Bangkok, Thailand

25 ^hDepartment of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok,
26 Thailand

27 ⁱDepartment of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn
28 University, Bangkok, Thailand

29 ^jDepartment of Medical Technology, Faculty of Allied Health Sciences, Thammasat
30 University, Pathumthani, Thailand

31 ^kResearch Unit in Molecular Pathogenesis and Immunology of Infectious Diseases,
32 Thammasat University, Pathumthani, Thailand

33 ^lResearch Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University,
34 Pathumthani, Thailand

35 ^mClinical Research Center, Faculty of Medicine, Thammasat University, Pathumthani,
36 Thailand

37

38 **Corresponding author:** Thanyawee Puthanakit, MD

39 Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics,
40 Faculty of Medicine, Chulalongkorn University

41 1873, Rama IV, Pathumwan, Bangkok, 10330, Thailand.

42 Telephone: +662 2564930

43 E-mail: thanyawee.p@chula.ac.th

44

45 * Contributed equally

46 **Additional study team members are listed in the Acknowledgments.

47

48 **Highlights**

49 - Low dose AZD1222 could boost comparable immunity to standard dose in healthy adult

50 who completed 2 doses of inactivated SARS-CoV-2 vaccines.

51 - Less reactogenicity occurred in low-dose AZD1222 booster than standard-dose recipients.

52

53 Word counts: 3487, Abstract 294

54 28 References, 2 Tables, 5 Figures, 1 Supplementary Table

55 Thai Clinical Trials Registry (thaiclinicaltrials.org): TCTR20210722003

56 **Abstract**

57 **Background:** Immunogenicity of inactivated SARS-CoV-2 vaccine has waning antibody
58 over time. With the emergence of the SARS-CoV-2 delta variant, which requires higher
59 neutralizing antibody to prevent infection, a booster dose is needed.

60 **Objective:** To evaluate immunogenicity and reactogenicity of standard- versus low-dose
61 ChAdOx1 nCoV-19 vaccine booster after CoronaVac in healthy adults.

62 **Methods:** A double-blinded, randomized, controlled trial of adult, aged 18-59 years, with
63 completion of 2-dose CoronaVac at 21-28 days apart for more than 2 months was conducted.
64 Participants were randomized to receive AZD1222 (Oxford/AstraZeneca) intramuscularly;
65 standard dose (SD, 5×10^{10} viral particles) or low dose (LD, 2.5×10^{10} viral particles).
66 Surrogate virus neutralization test (sVNT) against wild type and delta variant, and anti-spike-
67 receptor-binding-domain IgG (anti-S-RBD IgG) were compared as geometric mean ratio
68 (GMR) at day 14 and 90 between LD and SD arms.

69 **Results:** From July-August 2021, 422 adults with median age of 44 (IQR 36–51) years were
70 enrolled. The median interval from CoronaVac to AZD1222 booster was 77 (IQR 64–95)
71 days. At baseline, geometric means (GMs) of sVNT against delta variant and anti-S-RBD
72 IgG were 18.1%inhibition (95%CI 16.4-20.0) and 111.5 (105.1-118.3) BAU/ml. GMs of
73 sVNT against delta variant and anti-S-RBD IgG in SD were 95.6%inhibition (95%CI 94.3-
74 97.0) and 1975.1 (1841.7-2118.2) BAU/ml at day 14, and 89.4%inhibition (86.4-92.4) and
75 938.6 (859.9-1024.4) BAU/ml at day 90, respectively. GMRs of sVNT against delta variant
76 and anti-S-RBD IgG in LD compared to SD were 1.00 (95%CI 0.98-1.02) and 0.84 (0.76–
77 0.93) at day 14, and 0.98 (0.94-1.03) and 0.89 (0.79-1.00) at day 90, respectively. LD
78 recipients had significantly lower rate of fever (6.8%vs25.0%) and myalgia (51.9%vs70.7%)
79 compared to SD.

80 **Conclusion:** Half-dose AZD1222 booster after 2-dose inactivated SARS-CoV-2 vaccination
81 had non-inferior immunogenicity, yet lower systemic reactogenicity. Fractional low-dose
82 AZD1222 booster should be considered especially in resource-constrained settings.

83

84 **Keywords:** SARS-CoV-2 vaccine, booster dose, neutralizing antibody titer, anti-SARS-
85 CoV-2 IgG, CoronaVac vaccine, ChAdOx1 nCoV-19 vaccine, AZD1222

86

87 **Abbreviations**

88 BAU = Binding-antibody unit

89 BMI = Body mass index

90 CMI = Cell-mediated immunity

91 ELISpot = Enzyme-linked immunospot

92 GM = Geometric mean

93 GMR = Geometric mean ratio

94 LD = Low dose

95 PBMC = Peripheral blood mononuclear cell

96 SFU = Spot forming unit

97 S-RBD = Spike receptor binding domain

98 SD = Standard dose

99 sVNT = Surrogate virus neutralization test

101 **1. Introduction**

102 The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
103 respiratory syndrome coronavirus 2 (SARS-CoV-2), has global impacts, with over 330
104 million cases worldwide, and over 5 million deaths [1]. In Thailand, as of January 2022, more
105 than 2.3 million people with COVID-19 were reported with over 21,000 mortalities [1].
106 Moreover, the circulating SARS-CoV-2 has shifted from wild type WA1/2020 to several
107 variants of concern. Since May 2021, the B.167.2 (delta variant) was the major cause of
108 outbreak in many countries all over the world, including Thailand [2]. Variants of concern
109 contain amino acid changes in the receptor binding domain (RBD) of spike protein which is
110 the vaccine antigen. The neutralizing activity of serum samples from vaccinated persons
111 against B.167.2 variant was reduced, compared with WA1/2020 variant [3]. The change in
112 virus and waning of immunity after vaccination are driving forces for the necessity of a
113 booster dose vaccine. World Health Organization stated that COVID-19 vaccine booster
114 doses might be needed, considering on waning immunity, lower vaccine effectiveness against
115 variants of concern, and global vaccine coverage [4].

116 Multiple vaccine platforms against SARS-CoV-2, including inactivated vaccines, and
117 viral vector vaccines, have been rolled out in Thailand since March 2021. The inactivated
118 SARS-CoV-2 vaccine (CoronaVac, Sinovac Life Sciences, Beijing, China) was shown to be
119 effective in protecting against severe COVID-19 and COVID-19-related death, with two-dose
120 efficacy of 65.9% against COVID-19 and 86.3% against COVID-19-related death [5].
121 However, the efficacy of this vaccine gradually decreased during the extended follow-up
122 period, as shown by the increasing incidence of symptomatic SARS-CoV-2 infection in
123 immunized individuals [6] and waning immunity [7]. Furthermore, CoronaVac was shown to
124 induce lower neutralizing antibodies against variants of concern [8]. The ChAdOx1 nCoV-19
125 vaccine (AZD1222, Oxford/AstraZeneca) comprises a replication-deficient chimpanzee

126 adenoviral vector ChAdOx1, containing the SARS-CoV-2 structural surface glycoprotein
127 antigen (spike protein; nCoV-19) gene [9]. The report of randomized controlled trials of
128 AZD1222 showed overall vaccine efficacy of 90% and 70.4%, from low-dose priming group
129 and standard dose group, respectively [9]. The concept of fractional low dose was also shown
130 in several studies. A quarter dose of mRNA-1273 could generate spike-specific memory
131 CD4+ T cells in all participants and spike-specific CD8+ T cells in 88% of participants at 6
132 months after 2-dose completion, which were comparable in quantity and quality to COVID-
133 19 cases [10]. As a booster dose, half dose and one-fifth dose of mRNA-1273 could boost
134 neutralization titers against wild type and beta variant at 1 month after booster doses, given at
135 6 months after mRNA-1273 primary vaccination series [11].

136 Heterologous prime-boost vaccinations, the sequential administration of vaccines
137 using different antigen delivery systems [12], have been reported as a good strategy to
138 enhance cellular immune response against various viral pathogens including SARS-CoV-2
139 [13]. Studies on heterologous prime-boost vaccinations against SARS-CoV-2, using lipid
140 nanoparticle-formulated mRNA vaccine BNT162b2 (BioNTech/Pfizer) as a booster dose in
141 AZD1222-primed participants, showed significantly higher frequencies of spike-specific
142 CD4+ and CD8+ T cells than participants who received two-dose AZD1222 [14]. In
143 CoronaVac followed by AZD1222 vaccinees, the geometric mean of spike receptor binding
144 domain (S-RBD) IgG titers were higher than 2-dose AZD1222 vaccinees, with the level of
145 1492 BAU/ml and 178 BAU/ml, respectively [15]. Moreover, a recent study from Thailand
146 [16] showed that standard and half dose of BNT162b2 boosters after 2-dose inactivated
147 vaccine series increased both antibody and cellular immune response against SARS-CoV-2.

148 The objective of this study was to determine antibody response, cellular response, and
149 reactogenicity of standard versus low dose AZD1222 as a booster dose after completion of 2-
150 dose CoronaVac in healthy adult.

152 **2. Methods**

153 **2.1 Study design and participants**

154 This study took place at two clinical research centers: Faculty of Medicine,
155 Thammasat University, Pathum Thani, and Chulalongkorn University Health Center, Faculty
156 of Medicine, Chulalongkorn University, Bangkok, Thailand. This is a double-blinded,
157 randomized, controlled trial. Healthy adult, age 18 – 59 years old, who completed two doses
158 of CoronaVac for more than 60 days, with interval of 21 – 28 days were included in this
159 study. Participants who received any immunosuppressants or blood products within 3 months
160 or any vaccines within 2 weeks before study enrollment were excluded. All participants
161 provided written informed consent prior to study enrollment.

162 This study was registered in Thai Clinical Trials Registry (thaiclinicaltrials.org,
163 TCTR20210722003). Institutional review board of Faculty of Medicine, Thammasat
164 University (MTU-EC-PE1-182/64) and Faculty of Medicine, Chulalongkorn University (IRB
165 No. 600/64) approved this study.

166

167 **2.2 Study procedures**

168 The participants were stratified into two age strata, age 18 – 45 years and 46 – 59
169 years. The randomization process was performed using a block of two or four in sealed
170 envelope. The participants were vaccinated in participant-blinded fashion, with intramuscular
171 AZD1222 lot number A1009 and A10061, manufactured by Siam Bioscience Co., Ltd., 0.25
172 ml (2.5×10^{10} viral particles, low dose [LD]) or 0.5 ml (5×10^{10} viral particles, standard dose
173 [SD]). The vaccination was performed by unblinded nurses. Therefore, the participants and
174 blinded study team were not aware of the randomization arms. During the first 7 days after
175 vaccination, participants recorded the solicited local and systemic reactogenicity in the diary.

176 The solicited local and systemic reactogenicity included pain at injection site, swelling,
177 erythema, fever, feverish, headache, fatigue, myalgia, arthralgia (Chulalongkorn University
178 study site), vomiting, and diarrhea. Blood samples were collected prior to booster doses
179 administration. The follow-up visits were scheduled at day 14, and/or day 28, and day 90 to
180 collect solicited and unsolicited reactogenicity data and perform blood collection. All
181 participants' samples were tested for spike receptor binding domain IgG (anti-S-RBD IgG)
182 and surrogate virus neutralization test (sVNT) against wild type and B.167.2 (delta variant).

183 The cell-mediated immunity (CMI) sub study, to evaluate T and B cell responses, was
184 performed among 80 random participants, prior to vaccination, day 28, and day 90, using
185 enzyme-linked immunospot (ELISpot) assay.

186

187 **2.3 Immunogenicity outcomes**

188 2.3.1 Quantitative spike receptor binding domain IgG (anti-S-RBD IgG) ELISA

189 The ELISA protocol was adapted from Amanat *et al.* (2020) [17]. Briefly, diluted
190 serum samples were incubated in 96-well plates coated with purified recombinant Myc-His-
191 tagged S-RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1). Then, ELISA was
192 performed. Anti-S-RBD IgG level was reported in binding-antibody units (BAU/mL)
193 following conversion of OD450 values with the standard curve using known units of WHO
194 international standard (NIBSC 20/136). We used anti-S-RBD IgG level at 506 BAU/ml,
195 which is correlated with 80% vaccine efficacy reported by the Oxford COVID vaccine trial
196 group [18], as a cut off.

197

198 2.3.2 Surrogate virus neutralization test (sVNT)

199 A surrogate virus neutralization test was set up as previously described in Tan *et al.*
200 (2020) [19]. Recombinant SRBD from the wild-type (Wuhan-Hu-1) and delta (B.1.617.2)
201 strains were used. Serum samples (at 1:10 dilution) - SRBD mixture were incubated in 96-
202 well plates coated with 0.1 µg/well recombinant human ACE2 ectodomain (GenScript).
203 Then, ELISA was performed. The negative sample was pre-2019 human serum. The %
204 inhibition was calculated as follows:

$$\%inhibition = 100 \times \left[1 - \frac{sample OD450}{negative OD450} \right]$$

205

206 2.3.3 Enzyme-linked immunospot (ELISpot) assay to evaluate T and B cell responses

207 **T cell responses** were assessed by ELISpot assay using a Human IFN-γ
208 ELISpotPro™ kit (Mabtech, Stockholm, Sweden). Fresh peripheral blood mononuclear cells
209 (PBMCs) (250,000 cells per well) were stimulated with overlapping peptide pools from 100
210 peptides of SARS-CoV-2 Spike (S) defined peptides and 101 peptides from the nucleoprotein
211 (N), membrane protein (M) and open reading frame proteins (O) (Mabtech, Stockholm,
212 Sweden) for 20 hours. Negative control and positive control, anti-CD3, were also included.

213 **B cell responses** were assessed by Human IgG SARS-CoV-2 RBD ELISpot PLUS
214 (ALP) kit (Mabtech, Stockholm, Sweden). Briefly, fresh PBMCs (500,000 cells per well)
215 were pre-stimulated with R848 and IL-2 for 72 hours to allow memory B cells to differentiate
216 into antibody-secreting cells. Unstimulated well was also used as negative control. An RBD-
217 WASP antigen was added into RBD-specific IgG detected well while MT78/145-
218 biotinylated antibodies were added into total IgG detected well. Anti-WASP-ALP and
219 streptavidin-ALP were added into RBD-specific IgG detected well and total IgG detected
220 well, respectively.

221 The spots were counted using ImmunoSpot analyzer. Spot counts for negative control wells
222 were subtracted from the test wells to generate normalized readings, these are presented as
223 spot forming unit (SFU) per million PBMCs.

224 **2.4 Reactogenicity**

225 Solicited reactogenicity were assessed during the first 7-day period after booster
226 vaccination, by self-recording diary. Grading of adverse events are checked according to the
227 Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers
228 Enrolled in Preventive Vaccine Clinical Trials, 2007 [20]. Grading scale was grade 0 for no
229 symptoms; grade 1 for mild symptom, which was not interfere with activities or vomiting 1 –
230 2 times/day or diarrhea 2 – 3 times/day; grade 2 for moderate symptom, which interfered with
231 activities or needed medication for symptom relief, or vomiting more than 2 times/day or
232 diarrhea 4 – 5 times/day; grade 3 for severe symptom, which incapacitated or diarrhea 6 or
233 more times/day; grade 4 for potentially life-threatening symptom which required emergency
234 room visit or hospitalization. Fever was graded as grade 1 (38.0 – 38.4°C), grade 2 (38.5 –
235 38.9°C), grade 3 (39 – 40°C), and grade 4 (more than 40°C). Feverish was defined as feeling
236 of fever but body temperature less than 38.0°C. Unsolicited adverse events were also
237 recorded by study team at all visits.

238 **2.5 Statistical analysis**

239 The sample size was calculated using a non-inferiority criterion for the geometric
240 mean ratio (GMR) of sVNT against wild type and delta variant, and anti-S-RBD IgG,
241 comparing LD to SD. Assuming 0.75 non-inferiority margin, 90% power, and one-sided
242 statistical testing with 5% significance level, a minimum of 165 participants per group were
243 required. Accounting for potentially missing data, the sample size was increased by 20%,
244 yielding a total of 400 participants.

245 The demographic, laboratory data, and other continuous variables were described
246 using median (interquartile range [IQR]), while the categorical variables were described
247 using number with percentage. Wilcoxon rank sum test, chi-square or Fisher's exact test were
248 calculated to determine the differences in continuous and categorical variables between two
249 groups, respectively. The primary endpoints, GMR of sVNT against wild type and delta
250 variant, and anti-S-RBD IgG, comparing LD to SD at day 14 and 28 after booster, were
251 compared in terms of non-inferiority. Non-inferiority was established if the lower bound of
252 95% confidence interval (CI) of GMR was greater than 0.67 [21]. The geometric means
253 (GMs) were calculated as exponentiated means of logarithmic transformation of the assay
254 results. Two-sided 95% CIs were antilogarithm of titers from difference of two-independent
255 t-test. Anti-S-RBD IgG GM of at least 506 BAU/ml, the level corresponding with 80%
256 vaccine efficacy against symptomatic infection [18], was used as the protective cut-off level.
257 The reactogenicity rates were compared using chi-square test. All reported p-values are two-
258 sided. P values <0.05 were considered to be statistically significant. Statistical analysis was
259 performed using Stata version 15.1 (Stata Corp., College Station, Texas).

260 Correlation between the levels of anti-S-RBD IgG and receptor-blocking antibodies as
261 measured by sVNT was analyzed for both wild type and delta strains by non-linear regression
262 fit in GraphPad Prism 9 (GraphPad software, San Diego, CA). Data from the sub-population
263 with anti-S-RBD IgG titer below 1200 BAU/mL were used in the correlation analysis.

264

265 **3. Results**

266 **3.1 Baseline characteristics**

267 From July to August 2021, 422 adults with median age of 44 (IQR 36 – 51) years
268 participated. The trial profiles and demographic data are shown in Figure 1 and Table 1. The
269 median interval from 2nd dose of CoronaVac to AZD1222 booster dose was 77 days (IQR 64
270 – 95). Female was majority of the participants (50.7% in LD vs 53.6% in SD). Medians body
271 mass index (BMI) of participants were 24.7 kg/m² (IQR 21.9-27.7) in LD group and 24.8
272 kg/m² (IQR 22 – 28.1) in SD group. Approximately one-third of participants had
273 comorbidities e.g., hypertension, dyslipidemia, and diabetes mellitus. SD and LD groups had
274 similar GMs of sVNT to delta variant and wild type, with 18.1% inhibition (95% CI 16.4 –
275 20.0) and 36.0% inhibition (95% CI 33.6 – 38.6), respectively. GMs of anti-S-RBD IgG were
276 also comparable, with the level of 111.5 BAU/ml (95% CI 105.1 – 118.3).

277

278 **3.2 Reactogenicity**

279 Proportions of participants who had local and systemic reactogenicities were shown in
280 Figure 2 and Supplementary Table 1. LD recipients experienced significantly less systemic
281 reactogenicity than SD recipients i.e., fever which defined as $BT \geq 38^{\circ}C$ (LD, 6.8%; SD,
282 25%, p value <0.001), feverish (LD, 23.3%; SD, 38.9%, p-value <0.001), headache (LD,
283 54.9%; SD, 67.8%, p-value < 0.007), fatigue (LD, 63.1%; SD, 74.5%, p=0.01), and myalgia
284 (LD, 51.9%; SD, 70.7%, p<0.001). Severe local and systemic reactogenicity or grade 3
285 events also occurred less frequently in LD, ranging from 0 – 5.3% in LD and 0 – 9.6% in SD,
286 except vomiting. Grade 4 headache occurred in 1 SD participant, which improved by oral
287 analgesics.

288

289 **3.3 Immunogenicity**

290 **3.3.1 SARS-CoV-2 neutralizing antibody by surrogate virus neutralization test (sVNT)**

291 At 14 days post AZD1222 boosters, GMs of sVNT to delta variant were 95.6%
292 inhibition (95% CI 94.6 – 96.7) in LD group and 95.6% inhibition (94.3 – 97.0) in SD group,
293 as shown in Table 2 and Figure 3A. After 90 days, the GMs slightly decreased with the
294 results of 87.9% inhibition (95% CI 85.4 – 90.5) in LD group and 89.4% inhibition (86.4 –
295 92.4) in SD group. GMR of sVNT against delta variant of LD to SD showed non-inferiority
296 at both day 14 and day 90, with the value of 1.00 (95% CI 0.98 – 1.02) and 0.98 (0.94 –
297 1.03), respectively.

298 GMs of sVNT to wild type were slightly higher than to delta variant, with 96.5%
299 inhibition (95% CI 95.8 – 97.1) in LD group and 95.6% inhibition (93.3 – 97.8) in SD group
300 at 14 days after booster, as shown in Table 2. At day 90, the GMs were 92.1% inhibition
301 (95% CI 90.0 – 94.3) in LD group and 93.1% inhibition (91.0 – 95.2) in SD group, showing
302 similar trend as sVNT against delta variants. Non-inferior GMRs were also concluded at both
303 day 14 and day 90.

304 **3.3.2 SARS-CoV-2 binding antibody by anti-S-RBD IgG**

305 At day 14 post booster doses, anti-S-RBD IgG GMs were increased to 1663.5
306 BAU/ml (95% CI 1552.7 – 1782.2) in LD and 1975.1 BAU/ml (1841.7 – 2118.2) in SD, as
307 shown in Table 2 and Figure 3B. After 90 days, anti-S-RBD IgG GMs of both groups
308 declined, with 832.6 BAU/ml (95% CI 767.9 – 902.8) in LD and 938.6 BAU/ml (859.9 –
309 1024.4) in SD, however, the levels were still above 506 BAU/ml, the level correlating with
310 80% vaccine efficacy against symptomatic infection [18]. GMR of anti-S-RBD IgG
311 demonstrated non-inferiority of LD to SD at both day 14 and day 90. Subgroup analyses of
312 participants' characteristics on anti-S-RBD IgG at day 90; the results denoted the statistically

313 significant higher among SD group compared with LD group among participants in age > 45
314 years (SD: 1144BAU/ml (95%CI 683-1608) versus LD: 851BAU/ml (95%CI 556-1324), p
315 0.01), and BMI \geq 25 kg/m² (SD: 1245 BAU/ml (95% CI 654 – 1628) vs LD: 875 (95% CI
316 626 – 1309), p 0.03), respectively.

317 **3.4 Correlation between SARS CoV2 binding antibody and neutralization titer**

318 The levels of antibodies capable of inhibiting binding between hACE2 receptor and S-
319 RBD from both Wuhan and Delta strains were well-correlated with the levels of anti-RBD
320 IgG ($R^2 = 0.80$ for wild type and $R^2 = 0.84$ for delta strain). Correlation analyses between
321 anti-S-RBD IgG and sVNT from participants with anti-S-RBD less than 1200 BAU/ml at any
322 time points were shown in Figure 4. Only 8.1% of participants with anti-RBD IgG levels
323 higher than 1200 BAU/mL achieved lower than 95% inhibition levels in both sVNT assays.
324 From non-linear fits of data, the levels of anti-S-RBD IgG that gave 68% and 80% inhibition
325 against the wild type strain were approximately 298 (95% CI 291 – 305) and 472 (95% CI
326 452 – 494) BAU/mL, respectively. For the delta strain, these approximated anti-RBD IgG
327 levels were slightly higher at 498 (95% CI 480 – 518) and 742 (95% CI 704 – 786) BAU/mL,
328 respectively. The anti-S-RBD IgG level of 506 BAU/ml, the level correlating with 80%
329 vaccine efficacy against symptomatic infection during the Alpha (B.1.1.7) variant outbreak in
330 United Kingdom [18], is correlated with 81.8% inhibition of sVNT against wild type and
331 71% inhibition of sVNT against delta variant.

332

333

334 **3.5 Cell-mediated immune response by ELISpot assay**

335 The median frequencies of T cell response to SNMO peptides and RBD-specific B
336 cells with SARS-CoV-2 at baseline, and day 28 and day90 after booster dose are shown in
337 Figure 5. At baseline prior to AZD1222 booster, T cell response to SNMO peptides were 60
338 (IQR 32 – 100) cells/ 10^6 PBMCs in LD and 50 (20 - 84) cells/ 10^6 PBMCs in SD. At day 28
339 after receipt of booster, the median frequencies of SNMO-specific T cell response increased
340 to 104 (IQR 56 - 196) and 80 (40 - 108) cells/ 10^6 PBMCs in LD and SD group, respectively.
341 The median frequencies of RBD-specific B cells were very low at baseline; 1 (IQR 0 - 16)
342 cells/ 10^6 PBMCs in LD and 0 (0 - 6.5) cells/ 10^6 PBMCs in SD at day 0 and raised to 18 (8 -
343 42) and 26 (4 - 54) cells/ 10^6 PBMCs at day 28 in LD and SD group, respectively. Both T and
344 B cell responses were comparable between LD and SD group.

345 **4. Discussion**

346 The results showed that AZD1222 booster doses were able to boost immune
347 responses after 14 days to > 95% neutralizing inhibition against SARS-CoV-2 strains in
348 previous CoronaVac vaccinees. Low dose AZD1222 via intramuscular route had non-inferior
349 immunogenicity response to full dose of vaccine measured by anti-S-RBD IgG and surrogate
350 neutralizing antibodies, to both wild type and delta variant strains. Systemic reactogenicities
351 especially fever, headache, fatigue, and myalgia, developed in fewer LD participants than
352 those in SD group.

353 Solicited local and systemic adverse reactions after AZD1222 were more common
354 after the first doses [22]. Our study found higher rates of fever, feverish, headache, fatigue,
355 and myalgia in SD recipients. In participants receiving LD, headache, fatigue, myalgia, and
356 pain at injection site frequently developed than the previous report [22], yet lower than those
357 receiving SD. The less adverse reactions after LD AZD1222 may lead to more vaccine
358 acceptability, especially during this COVID-19 pandemic, when additional booster
359 vaccination might be needed.

360 The fractional low-dose concept of SARS-CoV-2 vaccine has been investigated. A
361 quarter dose of mRNA-1273 was able to generate T cell responses, both spike-specific
362 memory CD4+ T cells and spike-specific CD8+ T cells, in almost all of the participants at 6
363 months after 2 doses, which were comparable in quantity and quality to COVID-19 cases
364 [10]. In the view of immunological memory, lower antigen level could activate quicker and
365 stronger secondary immune response to previously encountered antigen [23]. Therefore, low-
366 dose vaccination could be an effective booster.

367 Feng et al. [18] reported that the anti-S-RBD IgG level associated with 80% vaccine
368 efficacy against symptomatic COVID-19 was 506 BAU/ml. For sVNT, 68% inhibition might

369 correlate with vaccine efficacy [24]. Based on these indicative cut-off levels, low dose
370 AZD1222 booster doses, in previous CoronaVac recipients, were effective. In phase 2/3 trials
371 of AZD1222, the low dose/standard dose cohort showed higher vaccine efficacy at 90%,
372 compared to 70.4% in standard dose group [9]. These findings also support that low dose
373 AZD1222 is the compelling choice if booster doses are needed.

374 Heterologous prime-boost schedule of COVID-19 vaccine was reported in many
375 studies. The Com-COV trial showed that, at 28 days post boost, the geometric mean
376 concentration of SARS-CoV-2 anti-spike IgG in AZD1222 followed by BNT162b2 schedule
377 was higher than 2-dose AZD1222 schedule [25]. Moreover, other study [14] and systematic
378 review [26] also reported robust immunogenicity of this heterologous administration of
379 AZD1222 followed by BNT162b2. Currently, CoronaVac has been widely used, with more
380 than 600 million doses delivered in more than 40 countries worldwide [27], with the
381 emergence of SARS-CoV-2 variants, the booster dose after completion of inactivated SARS-
382 CoV-2 vaccine schedule should be considered. The use of fractional low dose of COVID-19
383 vaccine could increase the vaccine coverage, while the vaccine supply is limited with only 15
384 percent vaccination coverage in Africa [28].

385 The strengths of this study were the double-blinded, randomized, controlled study
386 design, and multiple methods of immunologic assessments, both humoral and cellular
387 immunity, to wild type and variants of concern. We reported anti-S-RBD IgG and sVNT,
388 especially to delta variant which was the major cause of outbreak in many countries,
389 including Thailand. The limitation included the interval from last vaccination was only 2-3
390 months after completion of 2-dose CoronaVac. Though in the real world, the booster might
391 be given at longer interval from last CoronaVac, in which we expected to have at least similar
392 or even higher immunogenicity. Secondly, this study included healthy adults, and have no
393 data among high-risk groups, such as the elderly or the immunocompromised patients.

394 Thirdly, the follow up of the participants are ongoing to observe the kinetic of antibody
395 decline and risk of breakthrough infection if any occurred. Lastly, this study did not perform
396 sVNT for recently emerged variants e.g., Omicron, however, the comparable T cell responses
397 between standard and low dose AZD1222 booster could likely prevent severe symptoms of
398 COVID-19 caused by these variants.

399

400 **Acknowledgements**

401 Thank you for all study teams for their assistance with the study.

402 Faculty of Medicine, Thammasat University

403 Chulalongkorn University Health Service Center

404 Santhiti Dalan, MD, Supakanya Bintapanya, Kajeepat Rattanasrisompop, Pinyarat

405 Kitidumrongsook, Ratchadaporn Bamrungpipattanaporn, Nomjit Jirapattawong

406 Department of Microbiology, Faculty of Medicine, Chulalongkorn University

407 Pokrath Hansasuta, MD, Tysdi Laohasereekul, MD, Punyot Tovichayathamrong, MD,

408 Kasama Manothummetha, MD

409 Center of Excellence in Immunology and Immune-mediated Diseases, Department of

410 Microbiology, Faculty of Medicine, Chulalongkorn University

411 Vichaya Ruenjaiman, PhD, Supapit Horpratum, Jullada Thawilwang

412 Center of Excellence in Pediatric Infectious Diseases and Vaccines, Department of Pediatrics,

413 Faculty of Medicine, Chulalongkorn University

414 Puneyavee Aikphaibul, MD, Wipaporn Natalie Songtaweasin, MD, Tuangtip

415 Theerawit, Jitthiwa Athipunjapong, Thutsanum Meepuksom, Angsumalin Sutjarit,

416 Juthamanee Moonwong, Rachaneekorn Nadsasarn, Thidarat Jupimai, Pornpavee

417 Nuncharoen, Yanisar Chanpoom, Phattharapa Khamkhen

418 The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red

419 Cross AIDS Research Centre

420 Suwat Wongmueng, Palida Pingthaisong

421 National Center for Genetic Engineering and Biotechnology (BIOTEC)

422 Anan Jongkaewwattana, PhD, Kirana Yoohat, Channarong Seepiban, Jaraspim

423 Narkpuk, Thorntun Deangphare

424

425 **Funding**

426 The study was funded by the Ratchadapisek Sompoch Endowment Fund (2021) under
427 Health Research Platform (764002-HE07), Chulalongkorn University and Faculty of
428 Medicine, Thammasat University. This research is also supported by Ratchadapisek Somphot
429 Fund for Postdoctoral Fellowship, Chulalongkorn University.

430

431 **Conflict of interest**

432 The authors declare that they have no known competing financial interests or personal
433 relationships that could have appeared to influence the work reported in this paper.

434 **References**

- 435 1. WHO. WHO Coronavirus (COVID-19) Dashboard [Available from:
436 <https://covid19.who.int/>. Accessed date 20 January, 2022.
- 437 2. WHO. COVID-19 Weekly Epidemiological Update Edition 68, published 30 November
438 2021 2021 [Available from: [https://www.who.int/publications/m/item/weekly-epidemiological-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021)
439 [update-on-covid-19---30-november-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021). Accessed date 7 December, 2021.
- 440 3. Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection
441 and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *N*
442 *Engl J Med* 2021. <https://doi.org/10.1056/NEJMc2107799>
- 443 4. WHO. Interim statement on COVID-19 vaccine booster doses 2021 [updated 10 August
444 2021. Available from: [https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-](https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses)
445 [19-vaccine-booster-doses](https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-vaccine-booster-doses). Accessed date 29 August, 2021.
- 446 5. Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness
447 of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med* 2021.
448 <https://doi.org/10.1056/NEJMoa2107715>
- 449 6. WHO. Background document on the inactivated vaccine Sinovac-CoronaVac against
450 COVID-19 2021 [Available from: [https://www.who.int/publications/i/item/WHO-2019-nCoV-](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1)
451 [vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1). Accessed date 31
452 July 2021, 2021.
- 453 7. Jantarabenjakul W, Chantasrisawad N, Puthanakit T, Wacharapluesadee S, Hirankarn N,
454 Ruenjaiman V, et al. Short-term immune response after inactivated SARS-CoV-2
455 (CoronaVac(R), Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria(R), Oxford-AstraZeneca)

- 456 vaccinations in health care workers. *Asian Pac J Allergy Immunol* 2021.
457 <https://doi.org/10.12932/AP-250721-1197>
- 458 8. Vacharathit V, Aiewsakun P, Manopwisedjaroen S, Srisaowakarn C, Laopanupong T,
459 Ludowyke N, et al. CoronaVac induces lower neutralising activity against variants of concern
460 than natural infection. *The Lancet Infectious Diseases* 2021. [https://doi.org/10.1016/s1473-](https://doi.org/10.1016/s1473-3099(21)00568-5)
461 [3099\(21\)00568-5](https://doi.org/10.1016/s1473-3099(21)00568-5)
- 462 9. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety
463 and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
464 analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet*
465 2021;397:99-111. [https://doi.org/10.1016/s0140-6736\(20\)32661-1](https://doi.org/10.1016/s0140-6736(20)32661-1)
- 466 10. Mateus J, Dan JM, Zhang Z, Rydyznski Moderbacher C, Lammers M, Goodwin B, et al.
467 Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-
468 reactive T cells. *Science* 2021:eabj9853. <https://doi.org/10.1126/science.abj9853>
- 469 11. Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of
470 SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med*
471 2021. <https://doi.org/10.1038/s41591-021-01527-y>
- 472 12. Palgen JL, Feraoun Y, Dzangue-Tchoupou G, Joly C, Martinon F, Le Grand R, et al.
473 Optimize Prime/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game.
474 *Front Immunol* 2021;12:612747. <https://doi.org/10.3389/fimmu.2021.612747>
- 475 13. Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral
476 infections: Mechanisms and benefits. *Vaccine* 2016;34:413-23.
477 <https://doi.org/10.1016/j.vaccine.2015.11.062>

- 478 14. Barros-Martins J, Hammerschmidt SI, Cossmann A, Odak I, Stankov MV, Morillas
479 Ramos G, et al. Immune responses against SARS-CoV-2 variants after heterologous and
480 homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. *Nat Med* 2021.
481 <https://doi.org/10.1038/s41591-021-01449-9>
- 482 15. Yorsaeng R, Suntronwong N, Phowatthanasathian H, Assawakosri S, Kanokudom S,
483 Thongmee T, et al. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after
484 receiving two-dose inactivated vaccines in healthy adults. *Vaccine* 2021.
485 <https://doi.org/10.1016/j.vaccine.2021.11.083>
- 486 16. Intapiboon PS, P.; Ongarj, J.; Surasombatpattana, S.; Uppanisakorn, S.;
487 Mahasirimongkol, S.; Sawaengdee, W.; Phumiamorn, S.; Sapsutthipas, S.; Sangsupawanich, P.;
488 Chusri, S.; Pinpathomrat, N. Immunogenicity and Safety of an Intradermal BNT162b2 mRNA
489 Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population.
490 *Vaccines* 2021. <https://doi.org/10.3390/vaccines9121375>
- 491 17. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et
492 al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*
493 2020;26:1033-6. <https://doi.org/10.1038/s41591-020-0913-5>
- 494 18. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
495 against symptomatic and asymptomatic SARS-CoV-2 infection. *Nature Medicine* 2021.
496 <https://doi.org/10.1038/s41591-021-01540-1>
- 497 19. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al. A SARS-CoV-2 surrogate virus
498 neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein
499 interaction. *Nat Biotechnol* 2020;38:1073-8. <https://doi.org/10.1038/s41587-020-0631-z>

- 500 20. U.S. Department of Health and Human Services F, CBER. Guidance for Industry
501 Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive
502 Vaccine Clinical Trials September 2007 [Available from:
503 <https://www.fda.gov/media/73679/download>. Accessed date 30 November, 2021.
- 504 21. WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations, WHO
505 Technical Report Series 1004, Annex 9, 2017 2017 [Available from:
506 <https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9>. Accessed date 12
507 December, 2021.
- 508 22. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al.
509 Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost
510 regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3
511 trial. *The Lancet* 2020;396:1979-93. [https://doi.org/10.1016/s0140-6736\(20\)32466-1](https://doi.org/10.1016/s0140-6736(20)32466-1)
- 512 23. Ratajczak W, Niedzwiedzka-Rystwej P, Tokarz-Deptula B, Deptula W. Immunological
513 memory cells. *Cent Eur J Immunol* 2018;43:194-203. <https://doi.org/10.5114/ceji.2018.77390>
- 514 24. Tiwari AK, Negi G, Jaiswal RM, Aggarwal G, Yadav N, Kumar V, et al. Correlation of
515 sample to cut off ratio of anti SARS CoV 2 IgG antibody chemiluminescent assay with
516 neutralization activity: a prospective multi-centric study in India. *ISBT Science Series* 2021.
517 <https://doi.org/10.1111/voxs.12644>
- 518 25. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, et al. Safety and
519 immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral
520 vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-
521 inferiority trial. *Lancet* 2021;398:856-69. [https://doi.org/10.1016/S0140-6736\(21\)01694-9](https://doi.org/10.1016/S0140-6736(21)01694-9)

- 522 26. Chiu NC, Chi H, Tu YK, Huang YN, Tai YL, Weng SL, et al. To mix or not to mix? A
523 rapid systematic review of heterologous prime-boost covid-19 vaccination. *Expert Rev Vaccines*
524 2021;1-10. <https://doi.org/10.1080/14760584.2021.1971522>
- 525 27. Mallapaty S. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to
526 curbing pandemic. *Nature* 2021;594:161-2. <https://doi.org/10.1038/d41586-021-01497-8>
- 527 28. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al.
528 Coronavirus Pandemic (COVID-19) 2020 [Available from: <https://ourworldindata.org/covid->
529 vaccinations. Accessed date 24 January, 2022.

530

531

CONSORT 2010 Flow Diagram




Figure 1. Participants disposition flow diagram




Figure 2. Local and systemic reactogenicities within 7 days after AZD1222 booster in adult after 2 doses of inactivated vaccines, according to low dose and standard dose group.

Note: LD= low dose AZD (2.5 x 10¹⁰ viral particles), SD= standard dose (5 x 10¹⁰ viral particles)

The systemic reactions that are significant lower in the AZD1222 booster lower dose arm include: fever and feverish (p<0.001), headache (p<0.007), fatigue (p =0.01) and myalgia (p<0.001).




Figure 3A. Geometric means (95% CI) of sVNT to delta variant of SARS-CoV-2, at day 0 (before AZD1222 booster doses), day 14, day 28, and day 90 after booster doses in adult after 2 doses of inactivated vaccines.

P-value was evaluated by two-independent t-test.

LD: Low dose; SD: Standard dose; sVNT: Surrogate virus neutralization test




Figure 3B. Geometric means (95% CI) of anti-S-RBD IgG (BAU/ml), at day 0 (before AZD1222 booster doses), day 14, day 28, and day 90 after booster doses in adult after 2 doses of inactivated vaccines.

P-value was evaluated by two-independent t-test.

LD: Low dose; SD: Standard dose; S-RBD: Spike receptor binding domain




Figure 4. Correlation between anti-S-RBD IgG and sVNT to wild type (left) and delta variant (right) of SARS-CoV-2 at prior and post AZD1222 booster vaccination in adult after 2 doses of inactivated vaccines if anti-S-RBD IgG < 1200 BAU/ml. Dash lines represent 95% CI of fits of data.

S-RBD: Spike receptor binding domain, sVNT: Surrogate virus neutralization test, WT: Wild type




Figure 5. ELISpot assay at day 28 post AZD1222 booster in adult after 2 doses of inactivated vaccines, in low dose and standard dose group: (A) SNMO-specific T cell response, (B) RBD-specific B cell response.

RBD: Receptor binding domain; SFU: spot forming unit; SNMO: Spike (S) nucleoprotein (N), membrane protein (M), and open reading frame proteins (O) of SARS-CoV-2

Table 1. Baseline characteristics of study participants

	Total (N=422)	Low dose (N=211)	Standard dose (N=211)
Age (years), median (IQR)	44 (36 – 51)	44.4 (38 - 52)	43.5 (34.5 - 50)
- ≤ 45 years, n (%)	232 (55.0)	114 (54.0)	118 (55.9)
- >45 years, n (%)	190 (45.0)	97 (46.0)	93 (44.1)
Female, n (%)	220 (52.1)	107 (50.7)	113 (53.6)
BMI (kg/m²), median (IQR)	24.7 (22-27.7)	24.7 (21.9-27.7)	24.8 (22-28.1)
- < 25 kg/m ² , n (%)	225 (53.3)	114 (54.0)	111 (52.6)
- ≥ 25 kg/m ² , n (%)	197 (46.7)	97 (46.0)	100 (47.4)
Comorbidities, n (%)	136 (32.2)	74 (35.1)	62 (29.4)
- Hypertension, n (%)	38 (9.1)	18 (8.7)	20 (9.6)
- Diabetes mellitus, n (%)	3 (0.7)	-	3 (1.4)
- Dyslipidemia, n (%)	13 (3.1)	6 (2.9)	7 (3.4)
- Allergic rhinitis, n (%)	24 (5.8)	15 (7.3)	9 (4.3)
Interval between CoronaVac (days), median (IQR)	23 (21-28)	23 (21-28)	23 (21-28)
Interval between 2nd dose of CoronaVac to AZD1222 (days), median (IQR)	77 (64-95)	77 (64-95)	74 (63-95)
- 60-90 days, n (%)	283 (67.1)	141 (66.8)	142 (67.3)
- > 90 days, n (%)	139 (32.9)	70 (33.2)	69 (32.7)
sVNT to delta variant (%inhibition), GM (95% CI)	18.1 (16.4-20.0)	18.7 (16.4-21.4)	17.5 (15.1-20.3)
sVNT to wild type (%inhibition), GM (95% CI)	36.0 (33.6-38.6)	36.3 (32.8-40.2)	35.7 (32.4-39.3)
Anti-S-RBD IgG (BAU/ml), GM (95%CI)	111.5 (105.1-118.3)	116.2 (107.2-125.9)	107.0 (98.1-116.7)

BMI: Body mass index; GM: Geometric mean; S-RBD: Spike receptor binding domain; sVNT:

Surrogate virus neutralization test

Table 2. Results of sVNT to delta variant, sVNT to wild type, and anti-S-RBD IgG at day 14 and day 90, and non-inferior comparison between low dose and standard dose AZD1222 booster in adult after 2 doses of inactivated vaccines.

Immunogenicity outcomes	Low dose GM (95% CI)	Standard dose GM (95% CI)	GMR (95% CI) LD to SD
sVNT to delta variant (%inhibition)			
Day 14	(N=203) 95.6 (94.6-96.7)	(N=207) 95.6 (94.3-97.0)	(N=410) 1.00 (0.98-1.02)
Day 90	(N=200) 87.9 (85.4-90.5)	(N=202) 89.4 (86.4-92.4)	(N=402) 0.98 (0.94-1.03)
sVNT to wild type (%inhibition)			
Day 14	(N=203) 96.5 (95.8-97.1)	(N=207) 95.6 (93.3-97.8)	(N=410) 1.01 (0.99-1.03)
Day 90	(N=200) 92.1 (90.0-94.3)	(N=202) 93.1 (91.0-95.2)	(N=402) 0.99 (0.96-1.02)
Anti-S-RBD IgG (BAU/ml)			
Day 14	(N=209) 1663.5 (1552.7-1782.2)	(N=209) 1975.1 (1841.7-2118.2)	(N=418) 0.84 (0.76-0.93)
Day 90	(N=206) 832.6 (767.9-902.8)	(N=203) 938.6 (859.9-1024.4)	(N=409) 0.89 (0.79-1.00)

GM: Geometric mean; GMR: Geometric mean ratio; LD: Low dose; SD: Standard dose; S-RBD:

Spike receptor binding domain; sVNT: Surrogate virus neutralization test

Supplementary Table 1. Local and systemic reactogenicities[†] within 7 days after AZD1222 booster in adult after 2 doses of inactivated vaccines, according to low dose and standard dose group.

	Total	Low dose	Standard dose	
Reactogenicities	(N=414)	(N=206)	(N=208)	P-value[†]
	N (%)	N (%)	N (%)	
Local reactogenicities				
Pain	334 (80.7)	159 (77.2)	175 (84.1)	0.07
• Grade 1	217 (52.4)	110 (53.4)	107 (51.4)	
• Grade 2	89 (21.5)	39 (18.9)	50 (24.0)	
• Grade 3	28 (6.8)	10 (4.9)	18 (8.7)	
Swelling	10 (2.4)	4 (1.9)	6 (2.9)	0.53
• Grade 1	6 (1.5)	3 (1.5)	3 (1.4)	
• Grade 2	4 (1.0)	1 (0.5)	3 (1.4)	
Erythema	9 (2.2)	3 (1.5)	6 (2.9)	0.39
• Grade 1	6 (1.5)	3 (1.5)	3 (1.4)	
• Grade 2	2 (0.5)	-	2 (1.0)	
• Grade 3	1 (0.2)	-	1 (0.5)	
Systemic reactogenicities				
Fever	66 (15.9)	14 (6.8)	52 (25.0)	<0.001*
• Grade 1	33 (8.0)	10 (4.9)	23 (11.1)	
• Grade 2	21 (5.1)	3 (1.5)	18 (8.7)	

• Grade 3	12 (2.9)	1 (0.5)	11 (5.3)	
Feverish	129 (31.2)	48 (23.3)	81 (38.9)	0.001*
• Grade 1	114 (27.5)	43 (20.9)	71 (34.1)	
• Grade 2	15 (3.6)	5 (2.4)	10 (4.8)	
Headache	254 (61.4)	113 (54.9)	141 (67.8)	0.007*
• Grade 1	123 (29.7)	66 (32.0)	57 (27.4)	
• Grade 2	101 (24.4)	37 (18.0)	64 (30.8)	
• Grade 3	29 (7.0)	10 (4.9)	19 (9.1)	
• Grade 4	1 (0.2)	-	1 (0.5)	
Fatigue	285 (68.8)	130 (63.1)	155 (74.5)	0.01*
• Grade 1	171 (41.3)	92 (44.7)	79 (38.0)	
• Grade 2	83 (20.1)	27 (13.1)	56 (26.9)	
• Grade 3	31 (7.5)	11 (5.3)	20 (9.6)	
Myalgia	254 (61.4)	107 (51.9)	147 (70.7)	<0.001*
• Grade 1	156 (37.7)	70 (34.0)	86 (41.4)	
• Grade 2	84 (20.3)	33 (16.0)	51 (24.5)	
• Grade 3	14 (3.4)	4 (1.9)	10 (4.8)	
Arthralgia	(N=200) 33 (16.5)	(N=100) 12 (12.0)	(N=100) 21 (21.0)	0.09
• Grade 1	21 (10.5)	6 (6.0)	15 (15.0)	
• Grade 2	11 (5.5)	6 (6.0)	5 (5.0)	
• Grade 3	1 (0.5)	-	1 (1.0)	

Vomiting	39 (9.4)	17 (8.3)	22 (10.6)	0.42
• Grade 1	33 (8.0)	14 (6.8)	19 (9.1)	
• Grade 2	5 (1.2)	2 (1.0)	3 (1.4)	
• Grade 3	1 (0.2)	1 (0.5)	-	
Diarrhea	52 (12.6)	29 (14.1)	23 (11.1)	0.35
• Grade 1	48 (11.6)	28 (13.6)	20 (9.6)	
• Grade 2	4 (1.0)	1 (0.5)	3 (1.4)	

†Chi-square test

‡Adverse events grading according to U.S. Department of Health and Human Services F, CBER. Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials September 2007 [Available from: <https://www.fda.gov/media/73679/download>. Accessed date 30 November, 2021].

*p < 0.05